Results 91 to 100 of about 58,257 (262)

Real‐world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T‐cell therapy

British Journal of Haematology, EarlyView.
In this real‐world cohort of 231 patients receiving chimeric antigen receptor (CAR) T‐cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12‐month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71–1.94).
Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann‐Haefelin, Gabriel Allo, Philipp Kasper   +11 more
wiley   +1 more source

Editorial: Advances in the understanding and treatment of cutaneous lymphoma. [PDF]

Front Oncol, 2023
Bernardelli A, Falchi L, Qiao J, Visco C.   +3 more
europepmc   +1 more source

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, restores blood–brain barrier integrity in a human stem cell‐based model of ischaemic stroke

British Journal of Pharmacology, EarlyView.
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó, Koppány Párdi, Zuhao Cui, Gergő Porkoláb, Zsófia Hoyk, Csilla Kovács, Janet F. Adegbite, Virág Fodor, Nárcisz M. Cser, László Dér, Krisztina Nagy, Csilla Sajben, Roland Tengölics, Mária A. Deli, Szilvia Veszelka   +14 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

hMZF-2, the Elusive Transcription Factor

Frontiers in Genetics, 2020
Alain Chebly, Alain Chebly, Jean-Marie Peloponese, Evelyne Ségal-Bendirdjian, Jean-Philippe Merlio, Jean-Philippe Merlio, Roland Tomb, Roland Tomb, Edith Chevret   +8 more
doaj   +1 more source

OX-40 signaling promotes tumorigenesis in CTCL by regulating ERK activation

Frontiers in Immunology
IntroductionIn Cutaneous T-cell Lymphoma (CTCL), T cells can be activated either by cytokines produced by malignant T cells or through immunological synapses, such as the interaction between OX-40 and OX-40L on dendritic cells.
Evangelia Papadavid, Fani Karagianni, Eleni-Kyriaki Vetsika, Sara Valero-Díaz, Saire Edith Córdova-Hernández, Christos Daniil, Christina Piperi, Christina Piperi, Berta Casar, Berta Casar   +9 more
doaj   +1 more source

Biopsy of Iris and Anterior Chamber Tumours: Fine Needle, Minimally Invasive and Excision Techniques ‐ Review

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Several benign, inflammatory and malignant lesions can present as iris or anterior chamber masses, including iris naevi, cysts, adenomas, leiomyomas, nodules, vascular tumours, melanomas, metastases, as well as iris and pigment epithelium adenocarcinomas. Fortunately, benign iris lesions are much more common than malignant tumours and many can
Charles N. J. McGhee, Joevy Z. Lim, Peter W. Hadden, Jie Zhang   +3 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Subcutaneous Panniculitis-like T-cell Lymphoma

Clinical Dermatology Review
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a primary, rare cutaneous T-cell lymphoma that resembles panniculitis and accounts for
Sonal Mandli, Rutu Harsh Oza, Amita H Sutaria, Bela J Shah   +3 more
doaj   +1 more source

Recent advances in cutaneous lymphoma-implications for current and future classifications. [PDF]

Virchows Arch, 2023
Goodlad JR, Cerroni L, Swerdlow SH.
europepmc   +1 more source